Case History {#section1-0963689718755707}
============

Following a 30-mo period of worsening abdominal pain and fear of eating due to the associated epigastric pain and diarrhea, the male patient was diagnosed with severe chronic pancreatitis (CP; idiopathic). Between the onset of symptoms and the patient's first partial pancreas resection, the patient's weight had reduced from 108 kg (body mass index \[BMI\]: 36.5) to 63 kg (BMI: 21.3). At this stage, a Whipple procedure was performed, but only offered refractory relief from pain. Two years later, the patient was referred to Leicester, UK, and a completion pancreatectomy was carried out. At the time of the completion pancreatectomy, the patient was aged 55 y, and the CP was approaching end stage as evidenced by marked calcification of the remnant of the gland (confirmed by computed tomography scan and endoscopic retrograde cholangio-pancreatography assessment). Additionally, 3 mo before surgery, the patient showed "diabetic" endocrine function following an oral glucose tolerance test (5.55, 13, and 15.1 mmol/L at 0, 30 min and 2 h after a 75 g glucose bolus), again indicative of late-stage disease^[@bibr1-0963689718755707],[@bibr2-0963689718755707]^, although the previous resection may have contributed to this. At the time of surgery, the patient weighed just 45 kg (BMI: 15.2) and required 150 mg of opiate equivalents per day in an attempt to control his pain.

At the time of the completion pancreatectomy, the patient was not suffering with any other comorbidities; however, 15 y prior to the onset of CP, the patient had a trauma-related injury of the lower leg which had resulted in a below-the-knee amputation. This was not deemed to be associated with the later onset of CP.

Materials and Methods {#section2-0963689718755707}
=====================

The pancreatectomy procedure has been previously described^[@bibr3-0963689718755707]^. At the time of completion pancreatectomy, a specimen of pancreas was fixed for routine histological examination, although it must be noted that no samples were available for the first Whipple procedure.

In brief, specimens were sectioned and stained for insulin and glucagon in order to detect the prevalence of nonislet endocrine cells^[@bibr4-0963689718755707]^, cytokeratin 7 (CK7), and cytokeratin 19 (CK19) to estimate the prevalence of ductal epithelial cells and pancreatic and duodenal homeobox 1 (PDX-1) as a marker of pluripotent cells, as it is known to be expressed during pancreatic development and in the maturation of β cells. Further staining for synaptophysin and somatostatin was also carried out on the case patient for characterization purposes. Staining within islets was excluded from the data reported in [Table 1](#table1-0963689718755707){ref-type="table"}. All products were purchased from Dako (Glostrup, Denmark) with the exception of the insulin antibody (conditioned media derived from cell line HB124 of the Hybridoma Bank, Baltimore, MD, USA) and PDX-1 antibodies (R&D Systems, Abingdon, UK). Stained histological sections were assessed by analyzing 10 random fields (at 10× magnification) using Axiovision 4.7™ imaging software (Zeiss, Oberkochen, Germany) with the exception of glucagon. The Axiovision data presented here represent the mean percentage of positive pixels per field; however, it was recognized that the actual percentage of positive cells was likely to exceed the Axiovision figures quoted due to the fact that antibody staining was often restricted to either the nucleus or cytoplasm. Glucagon staining was carried out manually due to the fact that positive cells associated with the ductal epithelium needed to be counted separately, as such, glucagon data refer to the percentage of positive cells. The results of the case patient and the rest of the CP cohort (*n* = 22) and cadaveric pancreas samples (*n* = 8) are presented within [Table 1](#table1-0963689718755707){ref-type="table"}. Medians and ranges were used as descriptive statistics.

###### 

Patient and Histological Data Relating to the Case Patient and the Remaining Chronic Pancreatitis (CP) Cohort.

![](10.1177_0963689718755707-table1)

                                Case Patient   Remaining CP Cohort   Control Cohort
  ----------------------------- -------------- --------------------- -------------------
  *N*                           1              22                    8
  Age (y)                       55             43 (21--62)           54 (17--67)
  Previous pancreatic surgery   1              0                     0
  Etiology of CP                                                     
   Alcohol                      ---            8                     ---
   Idiopathic                   1              11                    ---
   Small duct disease           ---            1                     ---
   Pancreas divisum             ---            1                     ---
   Gallstones                   ---            1                     ---
  Smoker                        1              11                    2
  Weight (kg)                   45             61 (41--92)           ND
  BMI (kg/m^2^)                 15.2           22.0 (17.2--31.0)     28.6 (23.6--29.3)
  Insulin                       1.6            0.8 (0.2--4.5)        0.3 (0.2--0.5)
  Glucagon                      30.4           1.08 (0--3.9)         1.4 (0.5--3.1)
  Glucagon (ducts)              13.9           0.1 (0--1.5)          0.1 (0--0.6)
  PDX-1                         28.2           19.2 (7.10--34.0)     9 (4.6--17.1)
  CK7                           27.9           21.7 (12.9--41.0)     17.6 (8.7--38.7)
  CK19                          69.3           33.0 (8.4--75.4)      17.7 (13.1--20.3)

*Note*: Stained sections were assessed using Axiovision™ software, and the data reported refer to the percentage of positive pixels. The exception is glucagon that was manually counted due to the fact that the glucagon-positive cells associated with the ductal epithelium needed to be counted separately, as such these data refer to the percentage of glucagon-positive cells. Glucagon ducts refers to glucagon staining closely associated with the ductal epithelium. All staining reported refers to staining outside the islets of Langerhans. Data are described as medians (range). Etiology, previous pancreatic surgery, and smoker are presented as a proportion of the total.

Results {#section3-0963689718755707}
=======

Low weight is a signature of CP, however, the case patient fell well within the underweight category with a BMI of 15.2^[@bibr5-0963689718755707]^. Due to a previous Whipple procedure and atrophy caused by the CP, the remnant pancreas weighed just 22 g and exhibited a rigid and sclerotic gross morphology with visible calcium deposits.

Upon screening, the pancreatic biopsy showed marked replacement of acinar parenchyma with fibrotic tissue. Fibrotic areas were largely rich in islets ([Fig. 1a](#fig1-0963689718755707){ref-type="fig"}); however, within the fibrotic areas, the islet morphology was often distorted with islets exhibiting a flattened appearance ([Fig. 1c](#fig1-0963689718755707){ref-type="fig"}). Quantification of the immunohistochemistry staining showed higher levels of PDX-1-positive cells, ductal cells, and nonislet insulin-positive cells than the median values of the rest of the CP cohort ([Table 1](#table1-0963689718755707){ref-type="table"}). This is suggestive of significant acinar atrophy or high levels of regeneration within the case sample^[@bibr6-0963689718755707][@bibr7-0963689718755707]--[@bibr8-0963689718755707]^, although it was the prevalence of nonislet glucagon-positive cells that was particularly upregulated. In this patient, glucagon-positive cells were frequently shown to envelope medium-sized ducts ([Fig. 2a](#fig2-0963689718755707){ref-type="fig"}), and approximately 30-fold more were found in this patient than the median of the rest of the CP cohort ([Table 1](#table1-0963689718755707){ref-type="table"}).

![The abnormal architecture of the case patient sample. Staining with synaptophysin (pan-endocrine marker) showed that the tissue was largely islet rich (a and b), although in many areas the islets appeared crushed by the surrounding fibrotic tissue (c).](10.1177_0963689718755707-fig1){#fig1-0963689718755707}

![Hormone-positive cells associated with the ductal epithelium (consecutive sections). Glucagon-positive cells could be seen to completely envelope certain ducts and also surround budding structures that appeared to be new islets (a). Figure (b) and (c) show that insulin (b) and less frequently somatostatin-positive cells (c) were present within the budding structures. Figure (d) verifies that the structure is ductal through CK19 positivity.](10.1177_0963689718755707-fig2){#fig2-0963689718755707}

Additionally, within certain areas, ducts were shown to express significant levels of glucagon-positive cells (both viable and damaged) within their lumens ([Fig. 3](#fig3-0963689718755707){ref-type="fig"}). Further assessments of consecutive tissue sections showed that cells within the ductal lumens were negative for CK7, CK19, and insulin but positive for the pan-endocrine marker (synaptophysin). The presence of hormone-positive cells with duct lumens was not found in any other CP samples assessed.

![Hormone-positive cells within the duct lumen. Figure (a) shows hormone-positive (synaptophysin) cells (both viable and damaged) within the duct lumens. The consecutive sections show positive glucagon staining (b); however, the cells in the lumens were negative for insulin, somatostatin, and CK7 and CK19 staining (not shown).](10.1177_0963689718755707-fig3){#fig3-0963689718755707}

Discussion {#section4-0963689718755707}
==========

The pancreas of this patient demonstrated marked fibrosis but was also islet rich, and there were extremely high levels of glucagon associated with the ductal epithelium. The patient has a number of traits that may have contributed to this peculiar histological phenotype. CP^[@bibr6-0963689718755707],[@bibr9-0963689718755707],[@bibr10-0963689718755707]^, previous pancreatectomy/injury^[@bibr11-0963689718755707],[@bibr12-0963689718755707]^, and the onset of diabetes^[@bibr13-0963689718755707]^ create an ideal milieu for regeneration, and in particular CP is associated with an increase in the prevalence of ductal cells, PDX-1-positive cells, and intermediate cells^[@bibr6-0963689718755707][@bibr7-0963689718755707]--[@bibr8-0963689718755707]^. Likewise, extreme low weight (caused by anorexia nervosa coupled with Crohn's disease) has also been reported to induce a metaplastic change from the acinar phenotype into ductal cells^[@bibr14-0963689718755707]^. Although CP has certainly been reported to induce islet neogenesis, particularly in the later stages of the disease^[@bibr15-0963689718755707]^, in our experience, the level of glucagon-positive cells found surrounding the ductal epithelium was unusual. Based on the severe cachexia shown by the patient at the time of pancreatectomy, one could hypothesize that the apparent nesidioblastosis may represent an evolutionary attempt to maximize insulin output, thus increasing glucose uptake during times of severe starvation.

The most marked finding of the study was the total envelopment of sections of duct with glucagon-positive cells within areas of fibrosis ([Fig. 2a](#fig2-0963689718755707){ref-type="fig"}). Furthermore, glucagon-positive cells were frequently observed lining protrusions of the ductal epithelium which were frequently positive for both insulin and somatostatin ([Fig. 2b and c](#fig2-0963689718755707){ref-type="fig"}), suggesting that these "lobular" ducts lined with glucagon-positive cells represent zones of islet generation. Currently, there is much debate as to whether the mature ductal epithelium gives rise to new islet cells. As this histological study merely forms a snapshot of pancreas immunoreactivity, it cannot definitively prove that the duct epithelium gave rise to the hormone-positive cells. However, the involvement of the ductal epithelium can be in little doubt and this study, similar to numerous others, demonstrates a clear accumulation of islet cells in the close proximity to the ductal epithelium during pancreas regeneration^[@bibr16-0963689718755707][@bibr17-0963689718755707][@bibr18-0963689718755707][@bibr19-0963689718755707]--[@bibr20-0963689718755707]^. Additionally, in line with a case study by Soltani and colleagues, within this case study there was evidence of hormone-positive cells (in this case, glucagon-positive cells) within the lumen of some ducts^[@bibr9-0963689718755707]^. This mode of cell shedding is reminiscent of the disease course of pancreatic cancer where it is caused by enhanced proliferation rates of the ductal epithelium (reviewed by Jura and colleagues^[@bibr21-0963689718755707]^); however, the finding was unexpected, mainly due to the fact that no glucagon-positive cells were observed either intercalated with the ductal epithelial cells or attached to the luminal surface of the ductal epithelium ([Fig. 3](#fig3-0963689718755707){ref-type="fig"}). In line with the findings of Soltani and colleagues (2011) who reported insulin-positive cells within the duct lumens of a patient with severe CP^[@bibr9-0963689718755707]^, this finding suggests that ductal epithelium itself gives rise to or transdifferentiates into glucagon-positive cells. This theory is contentious, particularly as several lineage tracing studies in mice have shown that the ductal epithelium plays a negligible role in the neogenesis of new β cells^[@bibr22-0963689718755707][@bibr23-0963689718755707][@bibr24-0963689718755707]--[@bibr25-0963689718755707]^. However, the findings of these studies are balanced by lineage tracing studies by the Bonner-Weir group who have eloquently shown that labeled pancreatic ductal cells acted as progenitors that gave rise to new islets and acini both after birth and following injury (ductal ligation)^[@bibr26-0963689718755707],[@bibr27-0963689718755707]^.

Interestingly, while the case patient showed high levels of nonislet glucagon-positive cells, levels of nonislet insulin-positive cells were relatively moderate ([Table 1](#table1-0963689718755707){ref-type="table"}). This finding may reflect the fact that glucagon-positive cells have been shown to be the first hormone-positive cells to emerge during islet neogenesis^[@bibr28-0963689718755707],[@bibr29-0963689718755707]^, while based on our limited observations, insulin-positive cells emerged adjacent to the ductal epithelium as "islet-like clusters" surrounded by a layer of glucagon-positive cells ([Fig. 2a](#fig2-0963689718755707){ref-type="fig"}). It could be hypothesized that the case patient had undergone marked proliferation of both glucagon and insulin-positive cells, but the insulin cells emerged later in the islet neogenesis process and are therefore largely contained within the new islets. Indeed this hypothesis is supported by the fact that the pancreatic tissue analyzed is particularly islet dense ([Fig. 1](#fig1-0963689718755707){ref-type="fig"}).

The fact that whole cross sections of duct were surrounded by α cells demonstrates that under defined conditions the ductal epithelium has substantial potential for islet neogenesis. Future research defining the profile of factors causing new islet growth is an exciting possibility and could substantially contribute to studies assessing the potential of growing islets in vitro for transplantation purposes.

Conclusion {#section5-0963689718755707}
==========

In line with previous studies, this case study demonstrates the increased prevalence of ductal cells, PDX-1-positive cells, endocrine cells in response to severe mechanical insults (CP and partial pancreatectomy) and possibly physiological influences such as low body mass and the onset of diabetes. More specifically, this study highlights the substantial potential for α cell genesis close to the ductal epithelium. Knowledge of the factors involved in such marked α cell genesis may prove useful for growing pseudoislets in vitro for transplantation purposes.
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